Yiviva Wins 2 Top Awards at SAPA Investment Forum and Road Show for Innovative Systems Biology Approach to Treat Cancer
July 30, 2021 08:00 ET | Yiviva
NEW YORK and SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage biotechnology company that uses a systems-biology approach to treat aging-associated diseases, won two top...
Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular Carcinoma
April 06, 2020 07:00 ET | Yiviva
- First-in-class oncology therapeutic candidate YIV-906 applies an integrative systems biology approach -- Global study to evaluate efficacy, safety, and quality of life in patients with hepatitis...
April 06, 2020 07:00 ET | Yiviva
—— 利用整合系统生物学方法,由耶鲁大学郑永齐教授和医起共同开发的首个抗肿瘤候选植物药 中国上海,美国纽约, April 06, 2020 (GLOBE NEWSWIRE) -- 生物制药创新企业医起医药科技有限公司(Yiviva Inc.),在2020年初正式启动了YIV-906联合索拉非尼治疗乙型肝炎相关性肝细胞癌(HCC)的一线疗法IIb期研究,并于今年三月迎来了第一位受试者。 ...